We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stargardt Patient Treated With Retinal Pigment Epithelial Cells
News

Stargardt Patient Treated With Retinal Pigment Epithelial Cells

Stargardt Patient Treated With Retinal Pigment Epithelial Cells
News

Stargardt Patient Treated With Retinal Pigment Epithelial Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stargardt Patient Treated With Retinal Pigment Epithelial Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advanced Cell Technology, Inc. announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

The surgery was performed on Wednesday, July 11 at Wills Eye Institute in Philadelphia, by a surgical team lead by Carl D. Regillo, MD, FACS, director of the Wills Eye Clinical Retina Research Unit, attending surgeon in the Wills Eye Retina Service at the Wills Eye Institute, and professor of ophthalmology at Thomas Jefferson University. In keeping with trial protocol, the patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with the 50,000 cell dose used in the three patients of the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.

"It is very gratifying to have second cohort, higher-dosage patient treatment underway in our U.S. clinical trial for SMD," commented Gary Rabin, chairman and CEO of ACT. "We are also pleased to be working with Dr. Regillo and his team at Wills Eye Institute, a truly first-class institution that is ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report."

Initiated in July of last year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. As part of its RPE clinical program, the company is concurrently conducting a clinical trial for dry age-related macular degeneration and second trial for SMD in the United Kingdom.

"Doubling the cell dosage marks an important milestone in our clinical programs," said Robert Lanza, MD, ACT's chief scientific officer. "We look forward to continued progress and safety findings in the coming months, in both our U.S. and European trials."

Advertisement